Following news that Pharmasset (VRUS -3.4%) will discontinue Phase 2b trials of its hepatitis...

|By:, SA News Editor

Following news that Pharmasset (VRUS -3.4%) will discontinue Phase 2b trials of its hepatitis drug, other hepatitis-related companies are seeing dramatic share movement. Rallying: VRTX +3.9%, ACHN +1.4%. Declining: INHX -27%, IDIX -13.3%.